Biodel plummets after Linjeta complete response

Biodel Inc. (NASDAQ:BIOD) fell $1.50 (41%) to $2.13 on Monday after FDA issued a complete response letter and requested two new clinical trials for diabetes candidate Linjeta (formerly VIAject). The agency asked the company to conduct a new trial in each of Linjeta's proposed indications -- Type I and II diabetes -- to establish efficacy and safety as related to hypoglycemia and toleration. ...